Epizyme eyes lucrative use for newly-launched TazverikUS biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the Share XEpizyme eyes lucrative use for newly-launched Tazverikhttps://pharmaphorum.com/news/epizyme-eyes-lucrative-use-for-newly-launched-tazverik/
